OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,98 USD
arrow_upward
+1,12%(+0,055) 1 d.
16. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre OPHLY…
Otvoriť
5,05 USD
Vysoká
5,07 USD
Nízka
4,98 USD
Trh. kap.
1,20 bil.
Priem. obj.
62,80 tis.
Objem
20,91 tis.
Max. za 52 týž.
5,75 USD
Min. za 52 týž.
3,82 USD
Beta
0,21
Akcie v obehu
1,50 mld.
Počet zamestnancov
4 tis.
Otvoriť
5,05 USD
Vysoká
5,07 USD
Nízka
4,98 USD
Trh. kap.
1,20 bil.
Priem. obj.
62,80 tis.
Objem
20,91 tis.
Max. za 52 týž.
5,75 USD
Min. za 52 týž.
3,82 USD
Beta
0,21
Akcie v obehu
1,50 mld.
Počet zamestnancov
4 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
FOREX.com
·
pred 16 minútami
S&P 500, Nasdaq, Dow and Russell 2000 For the Week Ahead
tech-insider.org
·
pred 1 hodinou
Trump Calls AI Warnings ‘HOAX’, Nasdaq Drops 0.9% [2026]
Yahoo Finance
·
pred 16 hodinami
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
MarketWatch
·
pred 1 dňom
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Informácie o subjekte Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
Generálny riaditeľGyo Sagara | Gyo Sagara
Zamestnanci4,21 tis.
Dátum založenia1717
Hlavné sídloOsaka, Osaka, Japonsko
Odvetvie-